Equities research analysts expect Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to announce earnings per share of ($0.40) for the current quarter, according to Zacks. Zero analysts have made estimates for Corvus Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.41). Corvus Pharmaceuticals reported earnings per share of ($0.63) during the same quarter last year, which would suggest a positive year over year growth rate of 36.5%. The firm is expected to announce its next quarterly earnings report on Thursday, May 2nd.
On average, analysts expect that Corvus Pharmaceuticals will report full-year earnings of ($1.66) per share for the current year, with EPS estimates ranging from ($1.72) to ($1.60). For the next year, analysts expect that the firm will post earnings of ($1.81) per share, with EPS estimates ranging from ($1.83) to ($1.78). Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Corvus Pharmaceuticals.
Corvus Pharmaceuticals (NASDAQ:CRVS) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.10.
Several large investors have recently bought and sold shares of CRVS. Paloma Partners Management Co acquired a new position in shares of Corvus Pharmaceuticals in the fourth quarter worth about $58,000. Rhumbline Advisers boosted its holdings in shares of Corvus Pharmaceuticals by 44.1% in the fourth quarter. Rhumbline Advisers now owns 18,203 shares of the company’s stock worth $67,000 after buying an additional 5,570 shares during the period. Prudential Financial Inc. boosted its holdings in shares of Corvus Pharmaceuticals by 15.0% in the fourth quarter. Prudential Financial Inc. now owns 21,545 shares of the company’s stock worth $79,000 after buying an additional 2,805 shares during the period. Citadel Advisors LLC acquired a new position in shares of Corvus Pharmaceuticals in the third quarter worth about $182,000. Finally, Credit Suisse AG acquired a new position in shares of Corvus Pharmaceuticals in the third quarter worth about $194,000. Institutional investors own 85.71% of the company’s stock.
CRVS traded down $0.04 during midday trading on Monday, hitting $3.88. 1,491 shares of the company’s stock traded hands, compared to its average volume of 79,662. Corvus Pharmaceuticals has a one year low of $3.22 and a one year high of $13.91.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Featured Article: How to calculate the annual rate of depreciation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.